Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report

Published: February 12, 2026 Report Code: GDHC331PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Systemic Lupus Erythematosus and Lupus Nephritis market. The base year of the sales forecast model is 2024, and the forecast period is 2024-2034.
GlobalData estimated that the SLE and LN market was $2.4 billion accross the 7MM in 2024, increasing to $5.9 billion by 2034 at a compound annual growth rate (CAGR) of 9.6%. This growth was driven by the launch of ten late-stage pipeline agents entering a market prevouosly dominated by the off-label use of generic immunosuppressants, anti-malarials, and corticosteriods, offering a significant improvement in safety and efficacy. However, the market is expected to face signigicant barriers to its growth, most notably the entry of biosimilars such as belimumab and anifrolumab. And the slow adoption rate of pipeline therapeutics, due to the high annual cost of treatment associated with them.

Scope

Overview of SLE and LN – including epidemiology, disease etiology and management.

Topline SLE and LN drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.

Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global SLE and LN therapeutics market. Insightful review of the key industry drivers and barriers.

Key Highlights

The main driver of the enormous expansion of the SLE and LN market will be the launch of many different novel therapies and an increase in patient shares towards the biologics due to increased efficacy of these therapies.

The major global barrier for the SLE and LN market will be the annual cost of therapy for the new pipeline drugs

The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for SLE and LN patients with less occurrence of adverse events

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the seven-market systemic lupus erythematosus and lupus nephritis (SLE and LN) therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market SLE and LN market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the seven-market SLE and LN therapeutics market from 2024-2034.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
UCB
GSK
AstraZeneca
Roche
ImmuPharma
Autolus
Aurinia Pharmaceuticals
Idorsia Pharmaceuticals
Biogen
Bristol-Myers Squibb
RemeGen
Novartis
Viatris
Chugai

List of Contents

List of Tables

List of Figures

1 Systemic Lupus Erythematosus and Lupus Nephritis: Executive Summary

1.1 SLE market to significantly increase during the forecast period 2024–34

1.2 R&D strategies for the lupus market

1.3 High unmet need for steroid-sparing treatments that can reduce infection risk

1.4 Future SLE and LN players competition

1.5 Pipeline assessment

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Prognosis

3.3 Classification or staging systems

3.3.1 SLE classification

3.3.2 LN classification

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

Healthcare

2026. This product is licensed and is not to be photocopied.

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of SLE

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of SLE by severity

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of LN

4.4.6 Diagnosed prevalent cases of LN by class

4.5 Epidemiological forecast for diagnosed prevalent cases of SLE (2024–34)

4.5.1 Diagnosed prevalent cases of SLE

4.5.2 Age-specific diagnosed prevalent cases of SLE

4.5.3 Sex-specific diagnosed prevalent cases of SLE

4.5.4 Diagnosed prevalent cases of SLE by severity

4.5.5 Diagnosed prevalent cases of LN

4.5.6 Age-specific diagnosed prevalent cases of LN

4.5.7 Sex-specific diagnosed prevalent cases of LN

4.5.8 Diagnosed prevalent cases of LN by class

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 Treatment overview

5.3 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

6.2 SOC therapies in lupus

6.2.1 Antimalarials

6.2.2 Steroids

6.2.3 Immunosuppressive agents

6.3 Biologic therapies in lupus

6.3.1 Benlysta (belimumab)

6.3.2 Saphnelo (anifrolumab)

6.3.3 Gazyva/Gazyvaro (obinutuzumab)

6.3.4 Rituximab

Healthcare

2026. This product is licensed and is not to be photocopied.

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More efficacious therapies and steroid-free treatment

7.3 Infection prevention

7.4 Improving patient compliance

7.5 Development of biomarkers for lupus disease activity

8 R&D Strategies

8.1 Overview

8.1.1 Novel MoAs

8.1.2 Label Expansion and Reformulation

8.2 Clinical trial design

8.2.1 Design overview

8.2.2 Patient populations

8.2.3 CAR-T clinical trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

Healthcare

2026. This product is licensed and is not to be photocopied.

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist/Managing Epidemiologist

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

List of Tables

Table 1: SLE and LN: key metrics in the 7MM

Table 2 EULAR/ACR 2019 criteria for SLE classification

Table 3: Disease classification definitions in SLE

Table 4: BILAG=2004 index

Table 5 ISN/RPS 2018 classification of LN

Table 6: Risk factors and comorbidities for SLE

Table 7: 7MM, diagnosed prevalent cases of LN by class on the ISN/RPS classification, N, both sexes, all ages, 2024

Table 8 Treatment guidelines for SLE and LN

Table 9 Leading treatments for SLE and LN, 2025

Table 10 Clinical endpoints for recent and current Phase III SLE and LN pipeline assets

Table 11: Top 10 deals by value, 2020–25

Table 12 SLE and LN market – drivers and barriers in the US, 2024–34

Table 13: Key events impacting sales for SLE and LN in the US, 2024–34

Table 14: SLE and LN Market – drivers and barriers in the US, 2024–34

Table 15: Key events impacting sales for SLE and LN in the 5EU, 2024–34

Table 16: SLE and LN market – drivers and barriers in the 5EU, 2024–34

Table 17: Key events impacting sales for SLE and LN in Japan, 2024–34

Table 18: SLE and LN market – drivers and barriers in Japan, 2024–34

Table 20: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

List of Figures

Figure 1: Global sales forecast by country for SLE and LN in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in SLE/LN during the forecast period

Figure 3 Competitive assessment of the marketed and pipeline complex molecules benchmarked against the SOC, Benlysta

Figure 4 Competitive assessment of the marketed and pipeline small molecules benchmarked against the SOC,

mycophenolate mofetil

Figure 5 Overview of the etiology and pathogenesis of SLE

Figure 6 Integrated hypothesis for the pathogenesis of SLE

Figure 7: 7MM, diagnosed prevalence of SLE, men, women, %, all ages, 2024

Figure 8: 7MM, diagnosed prevalence of LN, men, women, %, all ages, 2024

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of SLE

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of SLE by severity

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of LN

Figure 12: 7MM, sources used to forecast the diagnosed prevalent cases of LN by class

Figure 13: 7MM, diagnosed prevalent cases of SLE, N, both sexes, all ages, 2024

Figure 14: 7MM, diagnosed prevalent cases of SLE by age, N, both sexes, 2024

Figure 15: 7MM, diagnosed prevalent cases of SLE by sex, N, all ages, 2024

Figure 16: 7MM, diagnosed prevalent cases of SLE by severity, N, both sexes, all ages, 2024

Figure 17: 7MM, diagnosed prevalent cases of LN, N, both sexes, all ages, 2024

Figure 18: 7MM, diagnosed prevalent cases of LN by age, N, both sexes, all ages, 2024

Figure 19: 7MM, diagnosed prevalent cases of LN by sex, N, men, women, all ages, 2024

Figure 20 Overview of the treatment management of SLE and LN

Figure 21: Unmet needs and opportunities in SLE and LN

Figure 22: Overview of the development pipeline in SLE in the 7MM

Figure 23: Overview of the development pipeline in LN in the 7MM

Figure 24 Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for SLE and LN in the

7MM during the forecast period

Figure 25 Competitive assessment of the marketed and pipeline small molecules benchmarked against the SOC,

mycophenolate mofetil

Figure 26 Competitive assessment of the marketed and pipeline complex molecules benchmarked against the SOC, Benlysta

Figure 27: Analysis of the company portfolio gap in SLE/LN during the forecast period

Figure 28: Global (7MM) sales forecast by country for SLE and LN in 2024 and 2034

Figure 29 Global (7MM) sales forecast by drug class for SLE and LN in 2024 and 2034

Figure 30 Sales forecast by drug class for SLE and LN in the US in 2024 and 2034

Figure 31 Sales forecast by drug class for SLE and LN in the 5EU in 2024 and 2034

Figure 32 Sales forecast by drug class for SLE and LN in Japan in 2024 and 2034

Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Systemic Lupus Erythematosus reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports